Pharmacogenetics and Statin Treatment: Reality or Theory?

被引：4

作者：

Bousoula, Eleni ^{[1
]}

Kolovou, Vana ^{[1
,2
]}

Perrea, Despoina ^{[3
]}

Kolovou, Genovefa ^{[1
]}

机构：

[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens 17674, Greece

[2] Onassis Cardiac Surg Ctr, Mol Immunol Lab, Athens 17674, Greece

[3] Univ Athens, Dept Expt Surg & Surg Res, Sch Med, GR-10679 Athens, Greece

来源：

CURRENT VASCULAR PHARMACOLOGY | 2015年 / 13卷 / 05期

关键词：

Statins; pharmacogenetics; gene polymorphisms; cholesterol; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; LIPID-LOWERING RESPONSE; CASSETTE TRANSPORTER A1; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; LIPASE GENE; CLINICAL-SIGNIFICANCE;

D O I：

10.2174/1570161113666150130165651

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics investigates heritable genetic polymorphisms that can effect responses to drug therapy. The main application of pharmacogenetics is genotype-guided dosing of medications and genotype-selection of treatment with the highest efficacy and lowest risk of adverse effects. Cardiovascular disease (CVD) is the leading cause of mortality and morbidity globally. Dyslipidemia is one of the classical risk factors for developing CVD. 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors called statins are the cornerstones in dyslipidemia treatment. However, there is a broad variation in individual responses to statin treatment. This variation may not only be due to environmental factors such as adherence to treatment, diet and exercise but also due to genetic factors. Many studies have focused on various genetic polymorphisms of genes that are involved in cholesterol metabolism, trying to define their contribution to a potential genotype-guided treatment against dyslipidemia.

引用

页码：616 / 623

页数：8

共 84 条

[1] Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages [J].

Aiello, RJ ;

Brees, D ;

Bourassa, PA ;

Royer, L ;

Lindsey, S ;

Coskran, T ;

Haghpassand, M ;

Francone, OL .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) :630-637

[2] Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects [J].

Anagnostopoulou, Katherine ;

Kolovou, Genovefa ;

Kostakou, Peggy ;

Mihas, Constantinos ;

Mikhailidis, Dimitri ;

Cokkinos, Dennis V. .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) :2459-2463

[3] Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia [J].

Anagnostopoulou, Katherine K. ;

Kolovou, Genovefa D. ;

Kostakou, Peggy M. ;

Mihas, Constantinos ;

Hatzigeorgiou, Georgios ;

Marvaki, Christina ;

Degiannis, Dimitrios ;

Mikhailidis, Dimitri P. ;

Cokkinos, Dennis V. .

LIPIDS IN HEALTH AND DISEASE, 2009, 8

[4]

[Anonymous], Global status report on blood safety and availability 2016

[5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6] Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction The GEOSTAT-1 Study [J].

Bailey, Kristian M. ;

Romaine, Simon P. R. ;

Jackson, Beryl M. ;

Farrin, Amanda J. ;

Efthymiou, Maria ;

Barth, Julian H. ;

Copeland, Joanne ;

McCormack, Terry ;

Whitehead, Andrew ;

Flather, Marcus D. ;

Samani, Nilesh J. ;

Nixon, Jane ;

Hall, Alistair S. ;

Balmforth, Anthony J. .

CIRCULATION-CARDIOVASCULAR GENETICS, 2010, 3 (03) :276-285

[7] Achieving greater reductions in cardiovascular risk: Lessons from statin therapy on risk measures and risk reduction [J].

Ballantyne, CM .

AMERICAN HEART JOURNAL, 2004, 148 (01) :S3-S8

[8] Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations [J].

Barber, Mathew J. ;

Mangravite, Lara M. ;

Hyde, Craig L. ;

Chasman, Daniel I. ;

Smith, Joshua D. ;

McCarty, Catherine A. ;

Li, Xiaohui ;

Wilke, Russell A. ;

Rieder, Mark J. ;

Williams, Paul T. ;

Ridker, Paul M. ;

Chatterjee, Aurobindo ;

Rotter, Jerome I. ;

Nickerson, Deborah A. ;

Stephens, Matthew ;

Krauss, Ronald M. .

PLOS ONE, 2010, 5 (03)

[9] Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment - Individual patient meta-analysis of 13,677 subjects [J].

Boekholdt, SM ;

Sacks, FM ;

Jukema, JW ;

Shepherd, J ;

Freeman, DJ ;

McMahon, AD ;

Cambien, F ;

Nicaud, V ;

de Grooth, GJ ;

Talmud, PJ ;

Humphries, SE ;

Miller, GJ ;

Eiriksdottir, G ;

Gudnason, V ;

Kauma, H ;

Kakko, S ;

Savolainen, MJ ;

Arca, M ;

Montali, A ;

Liu, S ;

Lanz, HJ ;

Zwinderman, AH ;

Kuivenhoven, JA ;

Kastelein, JJP .

CIRCULATION, 2005, 111 (03) :278-287

[10] The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease [J].

Carlquist, JF ;

Muhlestein, JB ;

Horne, BD ;

Hart, NI ;

Bair, TL ;

Molhuizen, HOF ;

Anderson, JL .

AMERICAN HEART JOURNAL, 2003, 146 (06) :1007-1014

← 1 2 3 4 5 6 7 8 9 →